Skip to main content
. 2025 Oct 27;17:2441–2457. doi: 10.2147/CMAR.S540752

Figure 3.

Figure 3

Diagnostic and prognostic value of serum tRF5-23-GlyTCC-2. (A) Serum expression levels of tRF5-23-GlyTCC-2 in colorectal cancer (CRC) patients (n=122), patients with colon polyps (n=71), and healthy donors (n=120). (B) Comparison of tRF5-23-GlyTCC-2 expression levels among CRC patients with varying depths of tumor invasion (T1–T2: n=49; T3–T4: n=73) and healthy donors (n=120). (C) Serum expression levels of tRF5-23-GlyTCC-2 in stage I–II CRC patients (n=53), stage III–IV patients (n=69), and healthy donors (n=120). (D) Differential expression levels of tRF5-23-GlyTCC-2 in CRC patients with (n=66) and without lymph node metastasis (n=56). (E) Expression levels of tRF5-23-GlyTCC-2 in CRC patients with (n=53) and without nerve/vascular invasion (n=69). (F) Serum tRF5-23-GlyTCC-2 levels in 57 CRC patients before and after surgical intervention. (G) Comparison of tRF5-23-GlyTCC-2 levels between postoperative CRC patients and healthy donors. (H) Kaplan-Meier survival curve illustrating the association between preoperative serum tRF5-23-GlyTCC-2 levels and CRC patient survival.